Finance

Lists
BOT:ASX
Botanix Pharmaceuticals Ltd
A$0.021
0.00%
(0.00) 1D
Sep 4, 4:10:25 PM GMT+10  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for BOT...
Open
A$0.02
High
A$0.02
Low
A$0.02
Mkt. cap
60.34M
Avg. vol.
7.45M
Volume
4.00M
52-wk high
A$0.17
52-wk low
A$0.02
EPS
-A$0.03
Shares outstanding
2.74B
No. of employees
11
Open
A$0.02
High
A$0.02
Low
A$0.02
Mkt. cap
60.34M
Avg. vol.
7.45M
Volume
4.00M
52-wk high
A$0.17
52-wk low
A$0.02
EPS
-A$0.03
Shares outstanding
2.74B
No. of employees
11
Profile
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company's lead product is Sofdra, which treats axillary hyperhidrosis. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
About Botanix Pharmaceuticals Ltd
CEO-
Employees11
Founded1984
Headquarters-
SectorPharmaceutical industry
Last report
Jul 26, 2026
Fiscal period
Q4 2026
EPS / Est. (AUD)
- / -
Revenue / Est. (AUD)
8.65M / -
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
8.25M
8.25M
8.65M
8.65M
Cost of goods sold
2.98M
2.98M
4.19M
4.19M
Cost of revenue
2.98M
2.98M
4.19M
4.19M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.32M
18.32M
19.70M
19.70M
Operating expense
22.08M
22.08M
22.30M
22.30M
Total operating expenses
25.06M
25.06M
26.49M
26.49M
Operating income
-16.81M
-16.81M
-17.85M
-17.85M
Other non operating income
683.30K
683.30K
109.28K
109.28K
EBT including unusual items
-16.60M
-16.60M
-18.29M
-18.29M
EBT excluding unusual items
-16.60M
-16.60M
-18.29M
-18.29M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16.60M
-16.60M
-18.29M
-18.29M
Net profit margin
-201.11%
-201.11%
-211.46%
-211.46%
Earnings per share
-
-
-
-
Interest and investment income
352.66K
352.66K
202.18K
202.18K
Interest expense
-802.39K
-802.39K
-616.20K
-616.20K
Net interest expenses
-449.74K
-449.74K
-414.02K
-414.02K
Depreciation and amortization charges
593.18K
593.18K
565.11K
565.11K
EBITDA
-16.22M
-16.22M
-17.28M
-17.28M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google apps